reference/17329346

http://rdf.ncbi.nlm.nih.gov/pubchem/reference/17329346

Outgoing Links

Predicate	Object
contentType	Clinical Trial, Phase I\|Journal Article\|Research Support, N.I.H., Extramural\|Research Support, Non-U.S. Gov't\|Research Support, U.S. Gov't, Non-P.H.S.
endingPage	3681
issn	0006-4971 1528-0020
issueIdentifier	12
pageRange	3674-3681
publicationName	Blood
startingPage	3674
hasFundingAgency	http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_b5ad88fdb9d8a30d34a9b7f844c05af4
isSupportedBy	http://rdf.ncbi.nlm.nih.gov/pubchem/grant/MD5_ee0fc474d30b25f64673edc931367078 http://rdf.ncbi.nlm.nih.gov/pubchem/grant/MD5_2f16c8a300919f58d3ea2212b43b08fb
bibliographicCitation	DeAngelo DJ, Stone RM, Heaney ML, Nimer SD, Paquette RL, Klisovic RB, Caligiuri MA, Cooper MR, Lecerf JM, Karol MD, Sheng S, Holford N, Curtin PT, Druker BJ, Heinrich MC. Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety, pharmacokinetics, and pharmacodynamics. Blood. 2006 Dec 01;108(12):3674–81. PMID: 16902153; PMCID: PMC1895460.
creator	http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_d6ce874d45143ef1d82314d09c19bd94 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_1c4f29909d3a1e3f60c7548094dbd0d1 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_dfbfde080329f2a03b45061d8368f265 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_4dba25dac778e35631aaa1a11ed1574c http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_28cf14f08787e7f3e1bb12d8421d48f4 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_aa64b16ef4ce67a27d847194f77f03ec http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_171301db3a17fbbf3bb255435aa525bd http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_38e3a7336fd99074423c1ebc8513978a http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_72d4fa1fc81c791c7bf4a12c3ffbda3f http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_b8ca3e3957c12668ab5c20fdb4be0b11 http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0002-4031-2514 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_c142315c6b5f9362e69c4762e0125be5 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_e39a34b1849b300977f1fd79e6c15b0d http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_6614c27331612dd1ce79265638fb74e4 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_1d1d887449fc783b38a4442de3ad2caa http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_78861806d92e41017c4024aa83e877c7
date	2006-12-01-04:00^^<http://www.w3.org/2001/XMLSchema#date>
identifier	https://doi.org/10.1182/blood-2006-02-005702 https://pubmed.ncbi.nlm.nih.gov/16902153 https://pubmed.ncbi.nlm.nih.gov/PMC1895460
isPartOf	https://portal.issn.org/resource/ISSN/0006-4971 http://rdf.ncbi.nlm.nih.gov/pubchem/journal/1243 https://portal.issn.org/resource/ISSN/1528-0020
language	English
source	https://www.crossref.org/ https://pubmed.ncbi.nlm.nih.gov/
title	Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety, pharmacokinetics, and pharmacodynamics
discusses	http://id.nlm.nih.gov/mesh/M0468902 http://id.nlm.nih.gov/mesh/M0190176 http://id.nlm.nih.gov/mesh/M0437922 http://id.nlm.nih.gov/mesh/M0028387 http://id.nlm.nih.gov/mesh/M0457532 http://id.nlm.nih.gov/mesh/M0016884 http://id.nlm.nih.gov/mesh/M0026515 http://id.nlm.nih.gov/mesh/M0018336
discussesAsDerivedByTextMining	http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID3038522 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7706 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_45bd205c63f9c9cfc7d5ba167cb355f0 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID9210 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID9731 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID10325 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID11449 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8560 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_5bf20507b757dd624886dac9baef5c7d http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8300

Incoming Links

Predicate	Subject
isDiscussedBy	http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID248315287 http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID175427013 http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID128865459

Total number of triples: 60.